

TERAPIA INTRAVITREALE NELLA CNV MIOPICA

XXXV Congresso S.O.si

C. Marino, G. Cascone, L. Rapisarda, G.
Pizzo , D. Lombardo

CNV MIOPICHE

sec a miopia patologica

-Errore refrattivo $>$ a -6D equiv.


Sferico

-lacquer cracks

-atrofia corioretinica peripapillare

-stafiloma posteriore

- A.L. $>$ 26.5 mm



TRATTAMENTO

FC LASER solo cnv extrafoveali

PDT terapia **STANDARD** dal 2001 cnv iuxta
e subfoveali (riduce la perdita di visus
rispetto al placebo) VIP study

ANTI VEGF intravitreali (**OFF LABEL**)

Ranibizumab (Lai 2009 (loading dose),
Mones 2009, Silva 2008)

Pegaptanib (bennet et al 2006)

Bevacizumab (Nguyen 2005, Sakaguchi 2007
Yamamoto 2007, Chan 2009 loading dose)

TERAPIE A CONFRONTO 2 aa

Battaglia Parodi et al .Arch Ophth. 2010

	Laser	pdt	IV bevacizumab
A.V	41%	27.5%	79%
Esten CNV	53%	72%	21%

CNV MIOPICHE NOSTRA ESPERIENZA

I.V. Avastin : 40 pz


-Protocollo terapeutico al bisogno

Ritrattamento se leakage alla FAG o liquido
intra o sottoretinico,


-Chiusura o fibrosi della CNV

G.R

I IV A.V. 4/10




II IV dopo 5 mesi A.V. 1.5/10



III IV




A.V. 4/10




IV IV A.V. 2/10


Dopo 4 mesi



V IV dopo 3 mesi



Contr post V A.V. 4/10



IRAC 2207009, OS, 461 FA 2-26-70 20"
Giordano, Rosario, 04/01/1937, #
Haidberg Engineering


IRAC 2207009, OS, 461 FA 2-26-70 20"
Giordano, Rosario, 04/01/1937, #
Haidberg Engineering

IRAC 2207009, OS, 461 FA 2-26-70 20"
Giordano, Rosario, 04/01/1937, #
Haidberg Engineering


A.M.

A.V. 5/10 I
IV

Dopo 1 mese



HSC 20140201_01_#17A.17.03.30
scanned with OCT1000 #
Heidelberg Engineering




Dopo 1 a. A.V.
10/10

Dopo 6 mesi




HSC 11032012_01_#17A.411.21.30
scanned with OCT1000 #
Heidelberg Engineering







S.R.


Pre A.V. 6/10 I/IV




II IV A.V. 8/10



Recidiva III
IV A.V. 8/10



1 a dopo A.V. 10/10



HRAL 17/12/2008, 05, 465 F.A. 3.20.11 30"
Dipartimento Oftalmologia, 10101948, P
Healthcare Engineering

L. 465 F.A. 3.25.10 30"
Dipartimento Oftalmologia, 10101948, P
Healthcare Engineering


HRAL 17/12/2008, 05, 465 F.A. 3.31.10 30"
Dipartimento Oftalmologia, 10101948, P
Healthcare Engineering

Pre A.V. 1/10
I IV








P.R.

3 mesi dopo
A.V. 2/10





C.S



CONCLUSIONI

- I.V. ANTIVEGF:
EFFICACE
- Incremento A.V.
- Riduzione del leakage
alla FAG e
dell'estensione della
CNV
- Riduzione dello
spessore retinico
centrale




CONCLUSIONI

ANTIVEGF



PDT



- Ridotto numero di iniezioni
- Assenza di eventi avversi **OCULARI** (rotture di retina, DR, atrofia corioretiniche) e **SISTEMICI**

GRAZIE